Table 1 Characteristics of Studies and patients
From: Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis
First author Year | Country/ Region | Study design | Antiviral regimens | Genotype | Weeks of treatment | SVR(W) | Number | Age (Years) | Males |
|---|---|---|---|---|---|---|---|---|---|
Jain [16] 2018 | India | prospective | SOF/DCV | G3 | 12 | SVR12 | 47 | 38 ± 13 | 60% |
Ichikawa [17] 2019 | Japan | retrospective | DCV/ASV | G1b | 24 | SVR24 | 38 | 70.92 ± 11.02 | 36% |
Ichikawa [18] 2019 | Japan | retrospective | Multiple DAA regimens | Multiple genotypes | 12/24 | SVR12 | 48 | 70.1 ± 11.08 | 42% |
Cheng [19] 2018 | Tai wan | prospective | SOF/DCV | G2 | 12 | SVR12 | 31 | 65.0 ± 13.2 | 28.10% |
Cheng [20] 2019 | Tai wan | prospective | Multiple DAA regimens | Multiple genotypes | 12/24 | SVR12 | 102 | 66.0 ± 10.7 | 33.30% |
AF 76 | 68.0 ± 9.3 | 32.90% | |||||||
NAF 26 | 60.3 ± 12.6 | 34.6% | |||||||
Gilmar [21] 2018 | Brazil | retrospective | Multiple DAA regimens | Multiple genotypes | 12/24 | SVR12 | 43 | 60.5 ± 9.5 | 27.90% |
Inoue [22] 2018 | Japan | NA | DCV/ASV | G1b | 24 | SVR24 | 69 | 68.3 ± 10.5 | 38.80% |
SOF/LDV | G1b | 12 | SVR24 | 84 | 64.4 ± 13.3 | 43.50% | |||
SOF/RBV | G2 | 12 | SVR24 | 45 | 62.0 ± 15.3 | 32.60% | |||
Gitto [23] 2018 | Italy | NA | Multiple DAA regimens | Multiple genotypes | 12/24 | SVR24 | 93 | 64 ± 12 | 60.20% |
El Sagheer [24] 2018 | Egypt | NA | SIM/SOF | G4 | 12 | SVR12 | 79 | 47 ± 12 | 58.80% |
Chida [25] 2018 | America | retrospective | DCV/ASV | G1b | 24 | SVR12 | 67 | 71 ± 9 | 40.00% |
Andrade [26] 2018 | Brazil | retro- prospective | Multiple DAA regimens | Multiple genotypes | 12 | SVR12 | 95 | 56 ± 9 | 70% |
Juanbeltz [27] 2017 | Spain | retrospective | Multiple DAA regimens | Multiple genotypes | 12/16/24 | SVR12 | 212 | 53.6 ± 9.3 | 71.80% |
Endo [28] 2017 | Japan | NA | DCV/ASV | G1b | 24 | SVR12 | 121 | 68.4 ± 11.8 | 48.80% |
SOF/LDV | G1b | 24 | SVR12 | 132 | 66.7 ± 13.1 | 37.10% | |||
Pedersen [14] 2016 | America | prospective | SOF/RBV | G2 | 12/24 | SVR12 | 58 | 55.5 ± 12.1 | 61.20% |
C 33 | |||||||||
NC 25 | |||||||||
SOF/RBV | G3 | 12/24 | SVR12 | 31 | 54.6 ± 10.8 | 64.50% | |||
C 14 | |||||||||
NC 17 | |||||||||
Shimizu [29] 2018 | Japan | NA | Multiple DAA regimens | G1/G2 | 12/24 | SVR12 | 70 | 66 (59–73) | 41.40% |
Beig [30] 2018 | New Zealand | retrospective | Multiple DAA regimens | NA | NA | SVR12 | 35 | NA | NA |
Sun [31] 2017 | Tai wan | NA | GZR/EBV or SOF/LDV | G1 | 12 | SVR12 | 22 | 60 (39 ~ 83) | 50% |
Doyle [32] 2019 | Canada | NA | PrOD | G1a/G1b | 12 | SVR12 | 23 | 54 ± 11.6 | 71% |
Muñoz.H [33] 2020 | NA | prospective | Multiple DAA regimens | Multiple genotypes | 12 | SVR12 | 109 | 53.6 ± 10.8 | 69.70% |
Sangineto [34] 2021 | Italy | retrospective | Multiple DAA regimens | NA | NA | SVR24 | 95 | 67.1 ± 0.8 | 50.60% |
Inomata [35] 2022 | Japan | retrospective | SOF/LDV | G1b | 12 | SVR12 | 22 | 60.5 (55–69) | 50% |
Graf [5] 2020 | Germany | retrospective | Multiple DAA regimens | Multiple genotypes | 12 | SVR24 | 45 | 51.7 ± 14.1 | 47.80% |
Chen [36] 2020 | Tai wan | prospective | Multiple DAA regimens | Multiple genotypes | 12/24 | SVR12 | 102 | 65.9 ± 9.9 | 32.40% |
Iossa [37] 2021 | Italy | retrospective | Multiple DAA regimens | Multiple genotypes | 12 | SVR24 | 47 | 66 (62–71) | 42.90% |
C 31 | |||||||||
NC 18 | |||||||||
Eletreby [38] 2021 | Egypt | prospective | SOF/DAC ± RBV | Multiple genotypes | 12/24 | SVR12 | 264 | 51.73 ± 10.24 | 89.20% |
Nevola [39] 2020 | Italy | prospective | Multiple DAA regimens | Multiple genotypes | 8–24 | SVR24 | 243 | 68 (62–74) | 46.90% |
Joshita [40] 2021 | Japan | retrospective | Multiple DAA regimens | Multiple genotypes | 8/12/24 | SVR12 | 231 | 70 (63–76) | 42.00% |
Abdoa [41] 2020 | Egypt | retrospective | SOF/DCV | NA | 12/24 | SVR12 | 98 | 51.54 ± 6.91 | 44.90% |
C 32 | |||||||||
NC 66 | |||||||||
Hino [42] 2021 | NA | retrospective | Multiple DAA regimens | Multiple genotypes | 12 | SVR12 | 67 | 70.0 (62–77) | 40.30% |
Anca [43] 2023 | Italy | retrospective | Multiple DAA regimens | NA | 12 | SVR12 | 132 | 61.17 ± 9.11 | 35.6% |
Ahmed [44] 2023 | Egypt. | retrospective | Multiple DAA regimens | NA | 12 | SVR12 | 100 | 50.99 ± 8.75 | 100% |
Diego [45] 2023 | Spain | retrospective | Multiple DAA regimens | Multiple genotypes | 8/12 | SVR12 | 83 | 55 (49–63) | 49.4% |